Fernando Himawan, Dinh Diem, Duffy Stephen J, Brennan Angela, Sharma Anand, Clark David, Ajani Andrew, Freeman Melanie, Peter Karlheinz, Stub Dion, Hiew Chin, Reid Christopher M, Oqueli Ernesto
Department of Cardiology, Alfred Hospital, Melbourne, Australia.
Atherothrombosis Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Int J Cardiol Heart Vasc. 2021 Mar 15;33:100745. doi: 10.1016/j.ijcha.2021.100745. eCollection 2021 Apr.
Fibrinolysis is an important reperfusion strategy in the management of ST-elevation myocardial infarction (STEMI) when timely access to primary percutaneous coronary intervention (PPCI) is unavailable. Rescue PCI is generally thought to have worse outcomes than PPCI in STEMI. We aimed to determine short- and long-term outcomes of patients with rescue PCI versus PPCI for treatment of STEMI.
Patients admitted with STEMI (excluding out-of-hospital cardiac arrest) within the Melbourne Interventional Group (MIG) registry between 2005 and 2018 treated with either rescue PCI or PPCI were included in this retrospective cohort analysis. Comparison of 30-day major adverse cardiac events (MACE) and long-term mortality between the two groups was performed. There were 558 patients (7.1%) with rescue PCI and 7271 with PPCI. 30-day all-cause mortality (rescue PCI 6% vs. PPCI 5%, p = 0.47) and MACE (rescue PCI 10.3% vs. PPCI 8.9%, p = 0.26) rates were similar between the two groups. Rates of in-hospital major bleeding (rescue PCI 6% vs. PPCI 3.4%, p = 0.002) and 30-day stroke (rescue PCI 2.2% vs. PPCI 0.8%, p < 0.001) were higher following rescue PCI. The odds ratio for haemorrhagic stroke in the rescue PCI group was 10.3. Long-term mortality was not significantly different between the groups (rescue PCI 20% vs. PPCI 19%, p = 0.33).
With contemporary interventional techniques and medical therapy, rescue PCI remains a valuable strategy for treating patients with failed fibrinolysis where PPCI is unavailable and it has been suggested in extenuating circumstances where alternative revascularisation strategies are considered.
在无法及时进行直接经皮冠状动脉介入治疗(PPCI)时,纤维蛋白溶解是ST段抬高型心肌梗死(STEMI)治疗中的一项重要再灌注策略。一般认为,补救性PCI在STEMI中的预后比PPCI差。我们旨在确定接受补救性PCI与PPCI治疗STEMI患者的短期和长期预后。
本回顾性队列分析纳入了2005年至2018年墨尔本介入治疗组(MIG)登记的因STEMI入院(不包括院外心脏骤停)且接受补救性PCI或PPCI治疗的患者。对两组的30天主要不良心脏事件(MACE)和长期死亡率进行了比较。有558例患者接受了补救性PCI(7.1%),7271例接受了PPCI。两组的30天全因死亡率(补救性PCI为6%,PPCI为5%,p = 0.47)和MACE(补救性PCI为10.3%,PPCI为8.9%,p = 0.26)发生率相似。补救性PCI后院内大出血发生率(补救性PCI为6%vs. PPCI为3.4%,p = 0.002)和30天卒中发生率(补救性PCI为2.2%vs. PPCI为0.8%,p < 0.001)更高。补救性PCI组出血性卒中的优势比为10.3。两组的长期死亡率无显著差异(补救性PCI为20%,PPCI为19%,p = 0.33)。
采用当代介入技术和药物治疗,补救性PCI仍然是治疗纤维蛋白溶解失败且无法进行PPCI患者的一项有价值的策略,并且在考虑替代血管重建策略的特殊情况下也有应用建议。